Advanced Care Management in Patients With Advanced Heart Failure

Overview

The purpose of this study is to explore the trajectory of advanced management care in patients with heart failure over a period of 9 months, then comparing the medical treatment accepted by patients after 2 years later and compliance with the preferences of patients and their families.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2020

Detailed Description

this study is to observe the trajectory of the advanced care management on patients with advanced heart failure and follow the difference between the actual medical treatment accepted by patients on 2years later and the preference of the patient and their families. the advance care management in this study is mean the patients who know about the preference of medical treatment, communication, and prognosis of illness. we also measure the sense of coherence, self-efficacy and their quality of life to compare their relationship of the advanced care management.

Arms, Groups and Cohorts

  • patient with advanced heart failure
    • we included the patients with advanced heart failure who had the poor cardiac function(LVEF<=30%) and was admitted to the general ward or emergency room within one year.

Clinical Trial Outcome Measures

Primary Measures

  • advanced care management
    • Time Frame: 3 months for each interval and 4 times on each patient (total 9 months on this study)
    • we use a modified questionnaire “assessment the medical needs and preference on terminal patients and their families (Tang, et al., 2004) by literature review and named “The prognosis and message status on patients with advanced Heart failure. the questionnaire include 3 parts: medical preference in their advanced status, communication between physician and patients and physician and their families ( the definition of families in this study is the major medical decision for the patients), and the knowledge of disease prognosis. The questionnaire include 17 items with continue and category variables. Before study we use expert validity from 5 experts who works in group at least 10 years. Each items is scored on a five-point Likert scale range from 0(not at all) to 4 (very appropriate to this study). The overall score was calculated as the average of all items and finally we got 3.67-points.

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosed with AHA stage D, or NYHA class function 4, or LVEF<=30%. – has one or more than one symptoms such as dyspnea, lower legs edema, weakness. – ever admission to the hospital (include emergency room or the general room) Exclusion Criteria:

  • with other end-stage diseases such cancer, dementia, COPD, ESRD…etc. – had other physical, cognitive, or psychological condition which may influence their answer.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • National Taiwan University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kai-di Kao, Principal Investigator, National Taiwan University Hospital
  • Overall Contact(s)
    • Kai-di Kao, +886928846909, keddy0717@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.